Korea United Pharm Inc. (033270.KS)
KRW 18480.0
(-1.75%)
KRW 18480.0
(-1.75%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 49.14 Billion KRW | 19.66% |
| 2022 | 41.06 Billion KRW | -3.22% |
| 2021 | 42.43 Billion KRW | -7.78% |
| 2020 | 46.01 Billion KRW | 14.7% |
| 2019 | 40.11 Billion KRW | 1.63% |
| 2018 | 39.47 Billion KRW | 16.66% |
| 2017 | 33.83 Billion KRW | 22.22% |
| 2016 | 27.68 Billion KRW | 8.06% |
| 2015 | 25.61 Billion KRW | -5.84% |
| 2014 | 27.2 Billion KRW | 0.51% |
| 2013 | 27.06 Billion KRW | -9.87% |
| 2012 | 30.03 Billion KRW | 32.15% |
| 2011 | 22.72 Billion KRW | 33.62% |
| 2010 | 17 Billion KRW | -1.24% |
| 2009 | 17.22 Billion KRW | 32.04% |
| 2008 | 13.04 Billion KRW | 35.49% |
| 2007 | 9.62 Billion KRW | 2.4% |
| 2006 | 9.4 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 52.62 Billion KRW | 7.09% |
| 2024 Q2 | 61.37 Billion KRW | 16.62% |
| 2023 Q4 | 49.14 Billion KRW | -11.22% |
| 2023 Q2 | 48.56 Billion KRW | 6.9% |
| 2023 FY | 49.14 Billion KRW | 19.66% |
| 2023 Q1 | 45.42 Billion KRW | 10.62% |
| 2023 Q3 | 55.35 Billion KRW | 13.99% |
| 2022 Q3 | 44.27 Billion KRW | 0.77% |
| 2022 Q1 | 42.33 Billion KRW | -0.24% |
| 2022 FY | 41.06 Billion KRW | -3.22% |
| 2022 Q2 | 43.92 Billion KRW | 3.77% |
| 2022 Q4 | 41.06 Billion KRW | -7.24% |
| 2021 Q4 | 42.43 Billion KRW | -1.97% |
| 2021 FY | 42.43 Billion KRW | -7.78% |
| 2021 Q1 | 46.33 Billion KRW | 0.69% |
| 2021 Q2 | 43.83 Billion KRW | -5.4% |
| 2021 Q3 | 43.28 Billion KRW | -1.25% |
| 2020 FY | 46.01 Billion KRW | 14.7% |
| 2020 Q1 | 45 Billion KRW | 12.2% |
| 2020 Q3 | 46.36 Billion KRW | 0.33% |
| 2020 Q4 | 46.01 Billion KRW | -0.75% |
| 2020 Q2 | 46.21 Billion KRW | 2.67% |
| 2019 Q4 | 40.11 Billion KRW | -2.66% |
| 2019 FY | 40.11 Billion KRW | 1.63% |
| 2019 Q1 | 40.47 Billion KRW | 2.55% |
| 2019 Q2 | 40.4 Billion KRW | -0.19% |
| 2019 Q3 | 41.21 Billion KRW | 2.0% |
| 2018 Q3 | 42.19 Billion KRW | 9.38% |
| 2018 Q1 | 36.39 Billion KRW | 7.55% |
| 2018 Q2 | 38.57 Billion KRW | 6.01% |
| 2018 FY | 39.47 Billion KRW | 16.66% |
| 2018 Q4 | 39.47 Billion KRW | -6.45% |
| 2017 Q1 | 29.64 Billion KRW | 7.08% |
| 2017 Q4 | 33.83 Billion KRW | -1.33% |
| 2017 Q3 | 34.29 Billion KRW | 10.47% |
| 2017 Q2 | 31.04 Billion KRW | 4.72% |
| 2017 FY | 33.83 Billion KRW | 22.22% |
| 2016 Q1 | 24.7 Billion KRW | 0.0% |
| 2016 Q4 | 27.68 Billion KRW | 0.86% |
| 2016 Q3 | 27.44 Billion KRW | 2.82% |
| 2016 Q2 | 26.69 Billion KRW | 8.06% |
| 2016 FY | 27.68 Billion KRW | 8.06% |
| 2015 Q2 | 25.67 Billion KRW | -1.27% |
| 2015 Q1 | 26 Billion KRW | -4.41% |
| 2015 Q3 | 26.06 Billion KRW | 1.5% |
| 2015 FY | 25.61 Billion KRW | -5.84% |
| 2014 Q1 | 29.86 Billion KRW | 10.33% |
| 2014 Q2 | 31.32 Billion KRW | 4.88% |
| 2014 FY | 27.2 Billion KRW | 0.51% |
| 2014 Q4 | 27.2 Billion KRW | -15.17% |
| 2014 Q3 | 32.07 Billion KRW | 2.39% |
| 2013 FY | 27.06 Billion KRW | -9.87% |
| 2013 Q2 | 28.06 Billion KRW | -5.47% |
| 2013 Q1 | 29.68 Billion KRW | -1.17% |
| 2013 Q4 | 27.06 Billion KRW | -4.65% |
| 2013 Q3 | 28.39 Billion KRW | 1.17% |
| 2012 Q4 | 30.03 Billion KRW | 0.0% |
| 2012 FY | 30.03 Billion KRW | 32.15% |
| 2012 Q1 | 23.47 Billion KRW | 0.0% |
| 2011 Q1 | 21.11 Billion KRW | 24.15% |
| 2011 Q2 | 23.69 Billion KRW | 12.2% |
| 2011 Q3 | 24.08 Billion KRW | 1.65% |
| 2011 FY | 22.72 Billion KRW | 33.62% |
| 2010 Q4 | 17 Billion KRW | 1.18% |
| 2010 Q1 | 17.01 Billion KRW | -1.22% |
| 2010 FY | 17 Billion KRW | -1.24% |
| 2010 Q2 | 16.13 Billion KRW | -5.15% |
| 2010 Q3 | 16.81 Billion KRW | 4.18% |
| 2009 Q3 | 16.08 Billion KRW | 14.94% |
| 2009 Q4 | 17.22 Billion KRW | 7.05% |
| 2009 Q2 | 13.99 Billion KRW | -1.9% |
| 2009 Q1 | 14.26 Billion KRW | 9.38% |
| 2009 FY | 17.22 Billion KRW | 32.04% |
| 2008 Q2 | 12.07 Billion KRW | 10.58% |
| 2008 Q3 | 12.68 Billion KRW | 5.1% |
| 2008 Q1 | 10.91 Billion KRW | 0.0% |
| 2008 FY | 13.04 Billion KRW | 35.49% |
| 2008 Q4 | 13.04 Billion KRW | 2.81% |
| 2007 Q2 | 9.06 Billion KRW | 0.0% |
| 2007 Q3 | 9.8 Billion KRW | 8.1% |
| 2007 FY | 9.62 Billion KRW | 2.4% |
| 2006 FY | 9.4 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -11.302% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 58.302% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 46.096% |
| HANDOK Inc. | 94.46 Billion KRW | 47.978% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -131.332% |
| Yuhan Corporation | 284.75 Billion KRW | 82.743% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 57.75% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -202.251% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 82.985% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -51.747% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 20.385% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -152.307% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -62.291% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | -1.644% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -11.302% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -57.301% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -39.702% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | -2.107% |
| JW Holdings Corporation | 147.58 Billion KRW | 66.704% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 41.929% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 81.203% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 53.68% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 8.867% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -82.021% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -51.153% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 55.231% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -11.302% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 73.95% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 79.655% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 53.68% |
| Yuhan Corporation | 284.75 Billion KRW | 82.743% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 60.774% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | 20.722% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 81.088% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 53.68% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 38.266% |
| CKD Bio Corp. | 69.08 Billion KRW | 28.864% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 53.233% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | 30.489% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | 9.094% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | 8.867% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 74.769% |
| Boryung Corporation | 189.8 Billion KRW | 74.109% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | 13.531% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | 20.385% |
| JW Lifescience Corporation | 23.39 Billion KRW | -110.021% |